Zogenix Shares Up 19.4% Premarket After Co. Announced Second Trial Success Of ZX008; Drug Reduced Monthly Convulsive Seizures By Over 50% vs Placebo In Children And Teenagers With Dravet's Syndrome, A Rare And Severe Type Of Epilepsy